Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomised, double blind, multi-centre, placebo controlled study to evaluate the efficacy and safety of methoxyflurane (Penthrox(TM)) for the treatment of acute pain in patients presenting to an Emergency Department with minor trauma

X
Trial Profile

A randomised, double blind, multi-centre, placebo controlled study to evaluate the efficacy and safety of methoxyflurane (Penthrox(TM)) for the treatment of acute pain in patients presenting to an Emergency Department with minor trauma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 15 Oct 2016

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Methoxyflurane (Primary)
  • Indications Acute pain; Musculoskeletal pain
  • Focus Registrational; Therapeutic Use
  • Acronyms STOP!
  • Sponsors Medical Developments International
  • Most Recent Events

    • 27 Aug 2016 Results of subgroup analysis (adult subgroup) published in the Advances in Therapy
    • 17 Jun 2015 New source identified and integrated (ClinicalTrial.gov: US National Institutes of Health)
    • 20 Oct 2012 Status changed from active, no longer recruiting to completed as reported by European Clinical Trials Database record.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top